EGFR associated expression profiles vary with breast tumor subtype

Hoadley, Katherine A; Weigman, Victor J; Cheng Fan; Sawyer, Lynda R; Xiaping He; Troester, Melissa A; Sartor, Carolyn I; Rieger-House, Thais; Bernard, Philip S; Carey, Lisa A; Perou, Charles M
January 2007
BMC Genomics;2007, Vol. 8, p258
Academic Journal
Background: The epidermal growth factor receptor (EGFR/HER1) and its downstream signaling events are important for regulating cell growth and behavior in many epithelial tumors types. In breast cancer, the role of EGFR is complex and appears to vary relative to important clinical features including estrogen receptor (ER) status. To investigate EGFR-signaling using a genomics approach, several breast basal-like and luminal epithelial cell lines were examined for sensitivity to EGFR inhibitors. An EGFR-associated gene expression signature was identified in the basal-like SUM102 cell line and was used to classify a diverse set of sporadic breast tumors. Results: In vitro, breast basal-like cell lines were more sensitive to EGFR inhibitors compared to luminal cell lines. The basal-like tumor derived lines were also the most sensitive to carboplatin, which acted synergistically with cetuximab. An EGFR-associated signature was developed in vitro, evaluated on 241 primary breast tumors; three distinct clusters of genes were evident in vivo, two of which were predictive of poor patient outcomes. These EGFR-associated poor prognostic signatures were highly expressed in almost all basal-like tumors and many of the HER2+/ER- and Luminal B tumors. Conclusion: These results suggest that breast basal-like cell lines are sensitive to EGFR inhibitors and carboplatin, and this combination may also be synergistic. In vivo, the EGFR-signatures were of prognostic value, were associated with tumor subtype, and were uniquely associated with the high expression of distinct EGFR-RAS-MEK pathway genes.


Related Articles

  • Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. Oishi, Yoko; Nagasaki, Koichi; Miyata, Satoshi; Matsuura, Masaaki; Nishimura, Sei-ichiro; Akiyama, Futoshi; Iwai, Takehisa; Miki, Yoshio // Journal of Human Genetics;Mar2007, Vol. 52 Issue 3, p271 

    The outcome of breast cancer patients with supraclavicular lymph node metastasis is generally poor, but some patients do survive for a long time. Consequently, the ability to predict the outcome is important in terms of choosing the appropriate therapy for breast cancer patients with...

  • Differential Gene Expression Pattern of Transforming Growth Factor Beta- 1 in Early and Advanced Breast Cancers. Dave, Heena V.; Shah, Manoj J.; Shukla, Shilin N.; Trivedi, Sunil N. // Journal of Cancer Science & Therapy;2011, Vol. 3 Issue 10, p244 

    Background: Transforming Growth Factor Bs (TGF-βs) are pluripotent polypeptides that switch function from growth suppressor to promoter during breast tumorigenesis. This integral function in tumor progression offers it as an attractive target of cancer therapy. Amongst the three mammalian...

  • The prognostic role of TGF-β signaling pathway in breast cancer patients. de Kruijf, E. M.; Dekker, T. J. A.; Hawinkels, L. J. A. C.; Putter, H.; Smit, V. T. H. B. M.; Kroep, J. R.; Kuppen, P. J. K.; van de Velde, C. J. H.; ten Dijke, P.; Tollenaar, R. A. E. M.; Mesker, W. E. // Annals of Oncology;Feb2013, Vol. 24 Issue 2, p384 

    Background The transforming growth factor-β (TGF-β) pathway has dual effects on tumor growth. Seemingly, discordant results have been published on the relation between TGF-β signaling markers and prognosis in breast cancer. Improved prognostic information for breast cancer patients...

  • The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer. Avery-Kiejda, Kelly A.; Braye, Stephen G.; Forbes, John F.; Scott, Rodney J. // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background: Breast cancer is the most common malignancy in women world-wide. Triple negative breast cancer (TNBC) is a highly aggressive subtype that lacks expression of hormone receptors for estrogen, progesterone and human epidermal growth factor 2; and is associated with a high propensity for...

  • Prognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis. Zhang, Zhiqiao; Luo, Guanying; Tang, Hongfeng; Cheng, Canchang; Wang, Peng // PLoS ONE;11/3/2016, Vol. 11 Issue 11, p1 

    Background: The prognostic significance of vascular endothelial growth factor C (VEGF-C) expression in breast cancer (BC) patients remains controversial. Therefore, this meta-analysis was performed to determine the prognostic significance of VEGF-C expression in BC patients. Materials and...

  • Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients. Syed, B. M.; Green, A. R.; Ellis, I. O.; Cheung, K. L. // Annals of Oncology;Apr2014, Vol. 25 Issue 4, p837 

    There is dearth of literature reporting the prevalence and biological characteristics as well as the long-term clinical outcome of HER2 overexpressing tumours in older women. Currently, research involving trastuzumab at large focuses on the younger population. This study showed less aggressive...

  • Concordance of HER-2/Neu over Expression with Steroid Receptor Status in Female Breast Cancers. Abdelhamid, Mohamed Salah; Abdelaziz, Solafa Amin; Daoud, Sahar Ali; Sadat, Ahmed Mohamed; Abdelhaseeb, Ayman Refaat; Nabil, Tamer Mohamed; Abdelbasset, Mohamed Salah; Nafady, Hesham Ahmed; Shawky, Khaled Ahmed; Abdelmoola, Mohamed Hasssen // Surgical Science;Aug2014, Vol. 5 Issue 8, p354 

    HER-2/neu over expression is associated with increased tumor aggressiveness, increased rates of recurrence, and increased mortality in node positive patients. It is amplified and/or over expressed in approximately 30% of female breast cancers. This study was to detect the relation between...

  • Gene-Expression Profiling and the Future of Adjuvant Therapy. Marc van de Vijver // Oncologist;Oct2005, Vol. 10 Issue 9, p30 

    Gene-expression profiling can help distinguish between patients at high risk and those at low risk for developing distant metastases, and so identify patients for adjuvant therapy. For several years, the Netherlands Cancer Institute has been working on gene-expression profiling of breast cancer...

  • Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. Wenjing Zhou; Jirström, Karin; Johansson, Christine; Amini, Rose-Marie; Blomqvist, Carl; Agbaje, Olorunsola; Wärnberg, Fredrik // BMC Cancer;2010, Vol. 10, p653 

    Background: Microarray gene-profiling of invasive breast cancer has identified different subtypes including luminal A, luminal B, HER2-overexpressing and basal-like groups. Basal-like invasive breast cancer is associated with a worse prognosis. However, the prognosis of basal-like ductal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics